Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of GSK Biologicals Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2013-2014 Season) in Adults Aged 18 Years and Older

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2013-2014 Season) in Adults Aged 18 Years and Older

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 1536489A (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Jan 2015 Protocol has been amended in treatment table from 1 arm to 2 arms, addition of primary endpoints , change of trial focus from 'PD' to TU & PD' and change of intervention model from single group to parallel assignment.
    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top